Takeda Pharmaceutical Co., Ltd., has discontinued the development of its TAK-361S vaccine, which was in clinical development Phase 2, Takeda said Monday.
TAK-361S is a four-component vaccine that combines diptheria-tetanus-acellular Pertussis with Sabin inactivated poliovirus (DTaP-sIP).
Takeda discontinued the vaccine in order to direct research and development resources to higher priority projects. The fact that safe and effective DTaP-sIP vaccines already exist also played a role in the decision.
Takeda plans to focus future vaccine programs on specific needs that are currently unmet in Japan and the world at large. Potential future projects include vaccines for dengue fever, Haemophilus Influenzae type B (Hib), norovirus, influenza, and Enterovirus 71, which is also known as hand, foot and mouth disease.
Takeda, the largest pharmaceutical company in Japan and Asia, first launched its global vaccine business in 2012. In 2013, Takeda submitted a new drug application for its Hib vaccine (TAK 816). The company continues to develop other vaccine solutions for seasonal influenza.
The Japanese government and public health professionals said an efficient norovirus vaccine is a high priority as such a vaccine is currently unavailable. Takeda currently has the best candidate for a norovirus vaccine worldwide.
In addition, Takeda is a leader among the pharmaceutical companies developing dengue vaccines. Such a vaccine would benefit 40 percent of the global population living in areas where dengue fever is common. Japan recently had its first dengue fever outbreak in almost 70 years.
Takeda’s norovirus and dengue fever vaccines are scheduled to begin Phase 3 clinical trials during fiscal years 2015 and 2016.